Cargando…

Cutaneous Toxicity in Oncologic Patients Receiving Epidermal Growth Factor Receptor Inhibitors

Background. In recent years, oncology studies have focused on molecular targeted therapy, based on the development of numerous agents with a role in inhibiting the epidermal growth factor receptor (EGFR). When overexpressed, EGFR plays an extremely important role in the growth of certain tumour cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	POPA, CRISTINA-MARIA, IANOŞI, SIMONA LAURA, SĂFTOIU, ADRIAN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medical University Publishing House Craiova 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987476/ https://www.ncbi.nlm.nih.gov/pubmed/35444828 http://dx.doi.org/10.12865/CHSJ.47.04.06

Ejemplares similares

Gut Microbiota Imbalance in Metastatic Colorectal Patients Treated With EGFRI and Long-Term Antibiotic Therapy for Cutaneous Toxicity: A Pilot Study
por: Popa, Cristina-Maria, et al.
Publicado: (2022)

The immunoexpression of epidermal growth factor receptor in cutaneous squamous cell carcinoma
por: Nichita, Mirela Marcela, et al.
Publicado: (2021)

Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors
por: Lupu, I, et al.
Publicado: (2015)

Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
por: Eaby-Sandy, Beth, et al.
Publicado: (2012)

The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
por: Owczarek, Witold, et al.
Publicado: (2017)

Molecular Profiling of EGFR Status to Identify Skin Toxicity in Colorectal Cancer: A Clinicopathological Review
por: POPA, CM, et al.
Publicado: (2019)

Expression of Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptor in Pancreatic Ductal Adenocarcinomas, Neuroendocrine Tumours and Chronic Pancreatitis
por: Angelescu, Radu, et al.
Publicado: (2013)

Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
por: Chanprapaph, K., et al.
Publicado: (2014)

A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor‐Induced Skin Toxicities
por: Kim, Young Saing, et al.
Publicado: (2019)

Epidermal Growth Factor Receptor Inhibitor Skin Rash Prophylaxis in a Community Oncology Setting
por: Pepper, Micah S., et al.
Publicado: (2018)

Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review
por: Leporini, Christian, et al.
Publicado: (2013)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors
por: Uprety, Dipesh, et al.
Publicado: (2020)

Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
por: Li, Yanping, et al.
Publicado: (2022)

Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas
por: Veloso, Emerson Soares, et al.
Publicado: (2020)

Epidermal growth factor receptor targeting and its role for individualisation in radiation oncology
por: Krause, Mechthild
Publicado: (2013)

The Epidermal Growth Factor Receptor Increases Cytokine Production and Cutaneous Inflammation in Response to Ultraviolet Irradiation
por: El-Abaseri, Taghrid Bahig, et al.
Publicado: (2013)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Role of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin Toxicities
por: Dsouza, Philomena Charlotte, et al.
Publicado: (2017)

Epidermal growth factor receptor inhibitors related trichomegaly of Eyelashes
por: Maka, Vinayak V., et al.
Publicado: (2014)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Clinical Profile of Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors: A Prospective Observational Study of 76 Cases
por: Saraswat, Neerja, et al.
Publicado: (2019)

Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis
por: Yang, Jingxuan, et al.
Publicado: (2010)

Toxic Epidermal Necrolysis-Like Lesions as Cutaneous Manifestation of Acute Methotrexate Toxicity
por: Singh, Raju, et al.
Publicado: (2020)

Epidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis
por: Moldan, Matthew M., et al.
Publicado: (2013)

Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Epidermal growth factor receptor inhibitor in advanced basal cell carcinoma
por: Amirabadi, Amir, et al.
Publicado: (2021)

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2
por: Tanaka, Hidekazu, et al.
Publicado: (2014)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma
por: Matsumura, Sosuke, et al.
Publicado: (2023)

Collagen sheet dressings for cutaneous lesions of toxic epidermal necrolysis
por: Bhattacharya, S., et al.
Publicado: (2011)

Ectodomain Shedding of Epidermal Growth Factor Receptor Ligands Is Required for Keratinocyte Migration in Cutaneous Wound Healing
por: Tokumaru, Sho, et al.
Publicado: (2000)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Epidermal growth factor receptor in glioblastoma
por: Xu, Hongsheng, et al.
Publicado: (2017)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

Molecular Determinants of Glioblastoma Response to Epidermal Growth Factor Receptor Kinase Inhibitors
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer
por: Henson, Elizabeth S, et al.
Publicado: (2007)

Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: ‘PRIDE’ Complex
por: Madke, Bhushan, et al.
Publicado: (2014)

Successful treatment of epidermal growth factor receptor inhibitor–induced alopecia with doxycycline
por: Chen, Chen (Amy), et al.
Publicado: (2015)

Identification of antiproliferative emodin analogues as inhibitors of epidermal growth factor receptor in cancer
por: Chen, Kuan-Chung, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qe2lj7aqln48htk16qdrqb1d02